

EXHIBIT G



U.S. Food & Drug Administration
 10903 New Hampshire Avenue
 Silver Spring, MD 20993
 www.fda.gov

PMTA Coversheet: Technical Project Lead Review (TPL)

SUBMISSION INFORMATION			
Applicant	Philip Morris Products S.A.		
Product Manufacturer	Philip Morris Products S.A.		
Submission Date	05-15-2017	FDA Receipt Date	05-15-2017
Primary STN(s)	PM0000424	Marlboro Heatsticks ¹	
	PM0000425	Marlboro Smooth Menthol Heatsticks ¹	
	PM0000426	Marlboro Fresh Menthol Heatsticks ¹	
	PM0000479	IQOS System Holder and Charger ¹	
Cross-referenced Submission(s)	Cross-referenced STN	Primary STN(s)	
	MR0000059	APPLIES TO PM0000424-PM0000426, PM0000479	
	MR0000060		
	MR0000061		
	MR0000133		
	MF0000013		
	MF0000243		
MF0000264			

¹ May be sold individually or as co-packaged product.

TABLE OF CONTENTS

I. EXECUTIVE SUMMARY 10

II. REVIEW OF PMTA 14

A. Regulatory History 14

B. Product Description: Engineering, Chemistry, Stability, and Manufacturing 14

 1. General 14

 2. Heatsticks 16

 a. Tobacco Ingredients 16

 b. Non-tobacco Ingredients 17

 c. Manufacturing, Process, and Controls 19

 d. Quality Assurance/Sample Testing 19

 e. Product Stability 22

 3. Heating System 25

 a. Holder 25

 b. Charger 25

 c. Manufacturing, Process, and Controls 25

 d. Quality Assurance/Sample Testing 26

 4. Inspections of Manufacturing Facilities 27

 5. Summary of Engineering, Chemistry, Product Stability, and Manufacturing Findings 29

C. Toxicological Risk Assessment 30

 1. Harmful and Potentially Harmful Constituents (HPHCs) 30

 a. General Overview 30

 b. Constituents Unique to IQOS 32

 c. Comparison to Cigarette Smoke 33

 d. Environmental Exposure from Heatstick Aerosol 35

 2. In Vitro Studies 35

 a. Neutral Red Uptake (NRU) Assays 35

 b. Bacterial Reverse Mutation (Ames) test 36

 c. Mouse Lymphoma Assay (MLA) 36

 d. Summary of In Vitro Studies 37

 3. In Vivo Studies 37

 a. 90-day Nose-only Inhalation Studies 37

 b. 18-month Carcinogenicity Study with A/J mice 38

 c. Nicotine Pharmacokinetic (PK) Study with Rats 38

 d. Summary 38

 4. Systems Toxicology Studies 39

 a. Acute and Repeated Exposure Studies with Human Organotypic Tissues 39

 b. ApoE^{-/-} Mouse Switching Study 39

 5. Nonclinical Evaluation of Carbon Monoxide from Heatstick Aerosol 40

 6. Summary of Toxicological Findings 41

D. Behavioral and Clinical Pharmacological Assessment	42
1. Pharmacokinetics, Exposure/Response and Clinical Pharmacology	42
a. Pharmacokinetic/Pharmacodynamic (PK/PD) Studies	42
b. Intrinsic and Extrinsic Factors Affecting Nicotine Pharmacokinetics	44
c. Nicotine Equivalents (NEQ) in Urine	44
d. Summary	45
2. Behavioral Pharmacology.....	45
a. Use Behavior and Topography.....	45
b. Product Use/Consumption.....	45
c. Product Acceptability.....	47
d. Abuse Liability.....	47
e. Summary.....	49
3. Summary of Behavioral and Clinical Pharmacology Findings.....	49
E. Individual Health Impact	50
1. Biomarkers of Exposure (BOE)	50
a. COHb – BOE for Carbon Monoxide	53
b. Monohydroxybutenyl-mercapturic acid (MHBMA) – BOE for 1,3-Butadiene	53
c. 3-Hydroxypropylmercapturic acid (3-HPMA) – BOE for Acrolein	54
d. S-phenylmercapturic acid (S-PMA) – BOE for Benzene	54
e. Total NNAL - BOE for NNK.....	54
f. CYP1A2 Activity.....	55
g. Urine Mutagenicity	55
h. Summary	55
2. Biomarkers of Potential Harm (BOPH)	56
a. Assessment of Inflammation	57
b. Assessment of Oxidative Stress	57
c. Assessment of Cardiovascular (CV) Risks.....	57
d. Assessment of Lung Function.....	57
e. Assessment of Genotoxicity and Mutagenicity.....	58
f. Summary	58
3. Clinical Effects of IQOS	59
a. Analysis of Adverse Events in Clinical Studies.....	59
b. Review of Published Clinical Literature.....	60
c. Summary.....	60
4. Likelihood of Product Misuse or Malfunction.....	61
5. Bioresearch Monitoring (BIMO) Inspection	62
6. 2017 Safety Update Report.....	62
7. Summary of Individual Health Findings from Clinical Studies, Literature, Adverse Experience Reports, and Safety Updates	64
F. Population Health	65
1. Likelihood of IQOS Use by Current Cigarette Smokers	68
2. Poly-use of IQOS and cigarettes or other tobacco products.....	72
3. Use of IQOS by Former or Never Smokers and Youth.....	73
4. Likelihood of IQOS leading to Conventional Cigarette Smoking Cessation.....	76

5. Population Modeling.....	77
6. Amendment MR0000117; Study ZRHR-ERS-09-US	79
7. Summary of Population Health Findings.....	83
III. PRODUCT LABELING, CONSUMER COMPREHENSION, AND MARKETING PLAN	85
A. Proposed PMTA Labeling.....	85
B. Consumer Comprehension.....	85
C. Marketing Plan	86
C. Nicotine is Addictive Labeling	87
D. Carbon Monoxide (CO) Warning.....	89
IV. CONCLUSIONS AND RECOMMENDATIONS	90
A. Recommendation for Marketing	98
B. Postmarketing Recommendations	99
C. Postmarketing Recordkeeping, Retention, Reporting and Marketing Requirements	99
1. Record Retention	100
2. Serious and Unexpected Adverse Experiences Reporting	102
3. Manufacturing Deviations.....	103
4. Periodic Reporting.....	103
5. Marketing Requirements	107
APPENDIX: THE PUBLIC HEALTH RATIONALE FOR RECOMMENDED RESTRICTIONS ON NEW TOBACCO PRODUCT LABELING, ADVERTISING, MARKETING, AND PROMOTION	111

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.